PTC THERAPEUTICS, INC.
PTCTAPI behind this page
PTCT FY 2025 request
Playground key active
/api/financials?ticker=PTCT&year=2025&quarter=4&full_year_mode=true
Pick an endpoint and run the request.Income Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Revenue (FY) | — | — | — |
Show Product Lines breakouts |
|||
| All other products | 37,264 | 36,946 | +0.9% |
| All other products · Non Us | 37,264 | 36,946 | +0.9% |
| Collaboration and license revenue | 998,357 | 304 | +328306.9% |
| Collaboration and license revenue · Novartis | 1 | — | — |
| Emflaza | 146,361 | 207,215 | -29.4% |
| Emflaza · US | 146,361 | 207,215 | -29.4% |
| Product | 586,703 | 582,145 | +0.8% |
| Product · Non Us | 334,518 | 374,930 | -10.8% |
| Product · US | 252,185 | 207,215 | +21.7% |
| Royalty | 244,224 | 203,864 | +19.8% |
| Royalty · Collaborative Arrangement | 244.2 | 203.9 | +19.8% |
| Sephience | 111,153 | — | — |
| Sephience · Non Us | 16,108 | — | — |
| Sephience · US | 95,045 | — | — |
| Translarna | 235,299 | 321,071 | -26.7% |
| Translarna | -98,629 | 18,806 | -624.5% |
| Translarna · Non Us | 235,299 | 321,071 | -26.7% |
| Translarna · Sales Returns And Allowances | 98.6 | — | — |
| Upstaza/Kebilidi | 56,626 | 16,913 | +234.8% |
| Upstaza/Kebilidi · Non Us | 45,847 | 16,913 | +171.1% |
| Upstaza/Kebilidi · US | 10,779 | — | — |
Show Business Segments breakouts |
|||
| Life Science · Operating Segments | 1,730,655 | 806,780 | +114.5% |
Show Geography breakouts |
|||
| All other countries | 168,412 | 197,472 | -14.7% |
| BR | 65,661 | 72,081 | -8.9% |
| Non Us | 235,888 | 393,736 | -40.1% |
| RU | 100,445 | 105,377 | -4.7% |
| US | 252,185,000 | 207,215,000 | +21.7% |
Show — breakouts |
|||
| Revenue | 1,730,655 | 806,780 | +114.5% |
| Cost Of Goods And Service Excluding Amortization Of Intangible Assets (FY) | — | — | — |
Show — breakouts |
|||
| Cost Of Goods And Service Excluding Amortization Of Intangible Assets | 47,013 | 57,398 | -18.1% |
| Amortization Of Intangible Assets (FY) | — | — | — |
Show Business Segments breakouts |
|||
| Life Science · Operating Segments | 24,742 | 60,738 | -59.3% |
Show — breakouts |
|||
| Amortization Of Intangible Assets | 24,742 | 60,738 | -59.3% |
Show Fair Value By Asset Class breakouts |
|||
| Finite Lived Intangible Assets | 24,742 | 60.7 | +40661.1% |
| Finite Lived Intangible Assets · Kebilidi | 894 | — | — |
| Finite Lived Intangible Assets · Sephience | 8,411 | — | — |
| Finite Lived Intangible Assets · Tegsedi | 3,860 | — | — |
| Finite Lived Intangible Assets · Upstaza | 8,911 | — | — |
| Finite Lived Intangible Assets · Waylivra | 2,666 | — | — |
| Research & Development (FY) | — | — | — |
Show — breakouts |
|||
| Research & Development | 455,249 | 534,480 | -14.8% |
| Selling, General & Administrative (FY) | — | — | — |
Show — breakouts |
|||
| Selling, General & Administrative | 347,143 | 300,911 | +15.4% |
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 (FY) | — | — | — |
Show — breakouts |
|||
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Asset1 | -800 | -4,475 | +82.1% |
| Gain Loss On Disposition And Impairment Of Tangible Assets (FY) | — | — | — |
Show — breakouts |
|||
| Gain Loss On Disposition And Impairment Of Tangible Assets | -9,627 | 750 | -1383.6% |
| Operating Expenses (FY) | — | — | — |
Show — breakouts |
|||
| Operating Expenses | 863,720 | 1,109,350 | -22.1% |
| Operating Income (FY) | — | — | — |
Show — breakouts |
|||
| Operating Income | 866,935 | -302,570 | +386.5% |
| Interest Income Expense Nonoperating Net (FY) | — | — | — |
Show — breakouts |
|||
| Interest Income Expense Nonoperating Net | -152,230 | -166,993 | +8.8% |
| Other Non-Operating Income (Expense) (FY) | — | — | — |
Show — breakouts |
|||
| Other Non-Operating Income (Expense) | -18,086 | 6,544 | -376.4% |
| Income Before Taxes (FY) | — | — | — |
Show — breakouts |
|||
| Income Before Taxes | 696,619 | -363,119 | +291.8% |
| Income Tax Expense (Benefit) (FY) | — | — | — |
Show Business Segments breakouts |
|||
| Life Science · Operating Segments | -13,975 | -176 | -7840.3% |
Show — breakouts |
|||
| Income Tax Expense (Benefit) | -13,975 | -176 | -7840.3% |
| Net Income (FY) | — | — | — |
Show Business Segments breakouts |
|||
| Life Science · Operating Segments | 682,644 | -363,295 | +287.9% |
Show Equity Components breakouts |
|||
| Retained Earnings | 682,644 | -363,295 | +287.9% |
Show — breakouts |
|||
| Net Income | 682,644 | -363,295 | +287.9% |
| Wtd Avg Shares (Basic) (FY) | — | — | — |
Show — breakouts |
|||
| Wtd Avg Shares (Basic) | 79,534,290 | 76,845,055 | +3.5% |
| Wtd Avg Shares (Diluted) (FY) | — | — | — |
Show — breakouts |
|||
| Wtd Avg Shares (Diluted) | 88,311,494 | 76,845,055 | +14.9% |
| EPS (Basic) (FY) | — | — | — |
Show — breakouts |
|||
| EPS (Basic) | 8.58 | -4.73 | +281.4% |
| EPS (Diluted) (FY) | — | — | — |
Show — breakouts |
|||
| EPS (Diluted) | 7.78 | -4.73 | +264.5% |
| Interest Expense (FY) | — | — | — |
Show Business Segments breakouts |
|||
| Life Science · Operating Segments | 226,308 | 214,307 | +5.6% |
| Interest Income (FY) | — | — | — |
Show Business Segments breakouts |
|||
| Life Science · Operating Segments | -74,078 | -47,314 | -56.6% |
| Comprehensive Income (FY) | — | — | — |
Show — breakouts |
|||
| Comprehensive Income | 719,031 | -387,896 | +285.4% |
| Other Comprehensive Income (FY) | — | — | — |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | 36,387 | -24,601 | +247.9% |
Show — breakouts |
|||
| Other Comprehensive Income | 36,387 | -24,601 | +247.9% |
| Net Income Loss Available To Common Stockholders Basic (FY) | — | — | — |
Show — breakouts |
|||
| Net Income Loss Available To Common Stockholders Basic | 682,644 | -363,295 | +287.9% |
| Labor And Related Expense (FY) | — | — | — |
Show Business Segments breakouts |
|||
| Life Science · Operating Segments | 283,583 | 251,184 | +12.9% |
Balance Sheet
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents (Q) | — | — | — |
Show — breakouts |
|||
| Cash & Cash Equivalents | 984,648 | 779,709 | +26.3% |
| Marketable Securities (Current) (Q) | — | — | — |
Show — breakouts |
|||
| Marketable Securities (Current) | 960,723 | 359,987 | +166.9% |
| Receivables Net Current (Q) | — | — | — |
Show — breakouts |
|||
| Receivables Net Current | 181,621 | 158,554 | +14.5% |
| Inventory (Q) | — | — | — |
Show — breakouts |
|||
| Inventory | 79,647 | 23,194 | +243.4% |
| Prepaid Expenses & Other Current Assets (Q) | — | — | — |
Show — breakouts |
|||
| Prepaid Expenses & Other Current Assets | 67,309 | 44,087 | +52.7% |
| Total Current Assets (Q) | — | — | — |
Show — breakouts |
|||
| Total Current Assets | 2,273,948 | 1,365,531 | +66.5% |
| Non-Current Assets | |||
| Property, Plant & Equipment (Q) | — | — | — |
Show Geography breakouts |
|||
| Non Us | 1,262 | 1,222 | +3.3% |
| US | 54,109 | 59,748 | -9.4% |
Show — breakouts |
|||
| Property, Plant & Equipment | 55,371 | 60,970 | -9.2% |
| Goodwill (Q) | — | — | — |
Show — breakouts |
|||
| Goodwill | 82,341 | 82,341 | 0.0% |
Show Business Acquisition breakouts |
|||
| Agilis | 82.3 | 82.3 | 0.0% |
| Operating Lease Right-of-Use Assets (Q) | — | — | — |
Show — breakouts |
|||
| Operating Lease Right-of-Use Assets | 80,053 | 56,685 | +41.2% |
Show Real Estate And Accumulated Depreciation Description Of Property breakouts |
|||
| Mountainview | 26.8 | — | — |
| Deposits And Other Assets Noncurrent (Q) | — | — | — |
Show — breakouts |
|||
| Deposits And Other Assets Noncurrent | 18,301 | 20,703 | -11.6% |
| Total Assets (Q) | — | — | — |
Show Geography breakouts |
|||
| Non Us | 373,732 | 361,790 | +3.3% |
| US | 2,525,035 | 1,343,234 | +88.0% |
Show — breakouts |
|||
| Total Assets | 2,898,767 | 1,705,024 | +70.0% |
| Intangible Assets (Q) | — | — | — |
Show — breakouts |
|||
| Intangible Assets | 388,753 | — | — |
Show Fair Value By Asset Class breakouts |
|||
| Finite Lived Intangible Assets | 388,753 | — | — |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill (Q) | — | — | — |
Show — breakouts |
|||
| Intangible Assets Net Excluding Goodwill | 388,753 | 118,794 | +227.2% |
| Current Liabilities | |||
| Accounts Payable And Accrued Liabilities Current (Q) | — | — | — |
Show — breakouts |
|||
| Accounts Payable And Accrued Liabilities Current | 381,272 | 304,292 | +25.3% |
| Current Portion of Long-Term Debt (Q) | — | — | — |
Show — breakouts |
|||
| Current Portion of Long-Term Debt | 286,631 | — | — |
| Deferred Revenue (Current) (Q) | — | — | — |
Show — breakouts |
|||
| Deferred Revenue (Current) | 2,040 | 5,505 | -62.9% |
| Operating Lease Liability Current (Q) | — | — | — |
Show — breakouts |
|||
| Operating Lease Liability Current | 12,484 | 10,363 | +20.5% |
| Finance Lease Liability Current (Q) | — | — | — |
Show — breakouts |
|||
| Finance Lease Liability Current | 3,000 | 3,000 | 0.0% |
Show Counterparty Name breakouts |
|||
| MassBio | 3 | 3 | 0.0% |
| Liability Sale Of Future Royalties Current (Q) | — | — | — |
Show — breakouts |
|||
| Liability Sale Of Future Royalties Current | 283,000 | 257,821 | +9.8% |
| Total Current Liabilities (Q) | — | — | — |
Show — breakouts |
|||
| Total Current Liabilities | 968,427 | 580,981 | +66.7% |
| Accounts Payable (Q) | — | — | — |
Show — breakouts |
|||
| Accounts Payable | 45,487 | 17,274 | +163.3% |
| Non-Current Liabilities | |||
| Operating Lease Liabilities (Q) | — | — | — |
Show — breakouts |
|||
| Operating Lease Liabilities | 93,583 | 74,947 | +24.9% |
| Finance Lease Liability Noncurrent (Q) | — | — | — |
Show — breakouts |
|||
| Finance Lease Liability Noncurrent | 3,000 | 15,574 | -80.7% |
Show Counterparty Name breakouts |
|||
| MassBio | 3 | 15.6 | -80.8% |
| Liability Sale Of Future Royalties Noncurrent (Q) | — | — | — |
Show — breakouts |
|||
| Liability Sale Of Future Royalties Noncurrent | 2,025,366 | 1,823,955 | +11.0% |
| Other Non-Current Liabilities (Q) | — | — | — |
Show — breakouts |
|||
| Other Non-Current Liabilities | 13,704 | 21,426 | -36.0% |
| Total Liabilities (Q) | — | — | — |
Show — breakouts |
|||
| Total Liabilities | 3,104,080 | 2,803,095 | +10.7% |
| Long-Term Debt (Q) | — | — | — |
Show Debt Instrument breakouts |
|||
| 2026 Convertible Notes · Convertible Debt | 286,631 | 285,412 | +0.4% |
| Stockholders' Equity | |||
| Common Stock (Q) | — | — | — |
Show — breakouts |
|||
| Common Stock | 80 | 77 | +3.9% |
| Additional Paid-In Capital (Q) | — | — | — |
Show — breakouts |
|||
| Additional Paid-In Capital | 2,748,335 | 2,574,611 | +6.7% |
| Accumulated Other Comprehensive Income (Q) | — | — | — |
Show — breakouts |
|||
| Accumulated Other Comprehensive Income | 10,501 | -25,886 | +140.6% |
| Retained Earnings (Q) | — | — | — |
Show — breakouts |
|||
| Retained Earnings | -2,964,229 | -3,646,873 | +18.7% |
| Total Stockholders' Equity (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Accumulated Net Unrealized Investment Gain Loss | 787 | 269 | +192.6% |
| Accumulated Other Comprehensive Income | 10,501 | -25,886 | +140.6% |
| Accumulated Translation Adjustment | 9,714 | -26,155 | +137.1% |
| Additional Paid In Capital | 2,748,335 | 2,574,611 | +6.7% |
| Common Stock | 80 | 77 | +3.9% |
| Retained Earnings | -2,964,229 | -3,646,873 | +18.7% |
Show — breakouts |
|||
| Total Stockholders' Equity | -205,313 | -1,098,071 | +81.3% |
| Total Liabilities & Equity (Q) | — | — | — |
Show — breakouts |
|||
| Total Liabilities & Equity | 2,898,767 | 1,705,024 | +70.0% |
Cash Flow Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization (FY) | — | — | — |
Show — breakouts |
|||
| Depreciation & Amortization | 38,815 | 75,663 | -48.7% |
| Operating Lease Right Of Use Asset Amortization Expense (FY) | — | — | — |
Show — breakouts |
|||
| Operating Lease Right Of Use Asset Amortization Expense | 7,467 | 7,752 | -3.7% |
| Noncash Royalty Revenue Sale Of Future Royalties (FY) | — | — | — |
Show — breakouts |
|||
| Noncash Royalty Revenue Sale Of Future Royalties | -228,568 | -181,507 | -25.9% |
| Noncash Interest Expense Liability Related To Sale Of Future Royalties (FY) | — | — | — |
Show — breakouts |
|||
| Noncash Interest Expense Liability Related To Sale Of Future Royalties | 215,158 | 207,394 | +3.7% |
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 (FY) | — | — | — |
Show — breakouts |
|||
| Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1 | -800 | -4,475 | +82.1% |
| Tangible Asset Impairment Charges (FY) | — | — | — |
Show — breakouts |
|||
| Tangible Asset Impairment Charges | 1,018 | 4,095 | -75.1% |
| Gain Loss On Sale Of Property Plant Equipment (FY) | — | — | — |
Show — breakouts |
|||
| Gain Loss On Sale Of Property Plant Equipment | 130 | 4,298 | -97.0% |
| Gain Loss On Modification Of Lease (FY) | — | — | — |
Show — breakouts |
|||
| Gain Loss On Modification Of Lease | -10,775 | -5,464 | -97.2% |
| Clearpoint Equity Investment Fvni Unrealized Gain Loss (FY) | — | — | — |
Show — breakouts |
|||
| Clearpoint Equity Investment Fvni Unrealized Gain Loss | -5,734 | -7,685 | +25.4% |
Show Investment Type breakouts |
|||
| ClearPoint Equity Investment | -5,734 | -7,685 | +25.4% |
| Clearpoint Equity Investment Fv Ni Realized Gain Loss (FY) | — | — | — |
Show — breakouts |
|||
| Clearpoint Equity Investment Fv Ni Realized Gain Loss | 7,081 | — | — |
Show Investment Type breakouts |
|||
| ClearPoint Equity Investment | 7,081 | — | — |
| Equity Securities Fv Ni Unrealized Gain Loss (FY) | — | — | — |
Show — breakouts |
|||
| Equity Securities Fv Ni Unrealized Gain Loss | -3,960 | -2,572 | -54.0% |
Show Investment Type breakouts |
|||
| Equity Securities | -3,960 | -2,572 | -54.0% |
| Gain Loss On Sale Of Other Assets (FY) | — | — | — |
Show — breakouts |
|||
| Gain Loss On Sale Of Other Assets | 163 | 345 | -52.8% |
| Deferred Income Taxes (FY) | — | — | — |
Show — breakouts |
|||
| Deferred Income Taxes | -3 | -55,912 | +100.0% |
| Accretion Amortization Of Discounts And Premiums Investments (FY) | — | — | — |
Show — breakouts |
|||
| Accretion Amortization Of Discounts And Premiums Investments | -18,022 | -12,529 | -43.8% |
| Amortization of Financing Costs (FY) | — | — | — |
Show Debt Instrument breakouts |
|||
| 2026 Convertible Notes · Convertible Debt | 1,219 | 1,198 | +1.8% |
Show — breakouts |
|||
| Amortization of Financing Costs | 1,219 | 1,198 | +1.8% |
| Stock-Based Compensation (FY) | — | — | — |
Show — breakouts |
|||
| Stock-Based Compensation | 74,547 | 74,615 | -0.1% |
| Foreign Currency Transaction Gain Loss Unrealized (FY) | — | — | — |
Show — breakouts |
|||
| Foreign Currency Transaction Gain Loss Unrealized | 3,380 | -10,374 | +132.6% |
| Change in Inventory (FY) | — | — | — |
Show — breakouts |
|||
| Change in Inventory | -53,896 | 6,164 | -974.4% |
| Change in Prepaid & Other Assets (FY) | — | — | — |
Show — breakouts |
|||
| Change in Prepaid & Other Assets | -36,818 | 98,763 | -137.3% |
| Increase Decrease In Receivables (FY) | — | — | — |
Show — breakouts |
|||
| Increase Decrease In Receivables | -10,151 | 1,732 | -686.1% |
| Increase Decrease In Deposit Other Assets (FY) | — | — | — |
Show — breakouts |
|||
| Increase Decrease In Deposit Other Assets | 2,638 | 12,459 | -78.8% |
| Increase Decrease In Accounts Payable And Accrued Liabilities (FY) | — | — | — |
Show — breakouts |
|||
| Increase Decrease In Accounts Payable And Accrued Liabilities | 71,741 | -33,322 | +315.3% |
| Increase Decrease In Other Operating Liabilities (FY) | — | — | — |
Show — breakouts |
|||
| Increase Decrease In Other Operating Liabilities | -17,396 | 11,830 | -247.0% |
| Change in Deferred Revenue (FY) | — | — | — |
Show — breakouts |
|||
| Change in Deferred Revenue | -3,998 | 4,917 | -181.3% |
| Increase Decrease In Contingent Consideration (FY) | — | — | — |
Show — breakouts |
|||
| Increase Decrease In Contingent Consideration | -4,684 | -1,800 | -160.2% |
| Net Cash from Operations (FY) | — | — | — |
Show — breakouts |
|||
| Net Cash from Operations | 711,196 | -107,688 | +760.4% |
| Investing Activities | |||
| Capital Expenditures (FY) | — | — | — |
Show — breakouts |
|||
| Capital Expenditures | -8,860 | -6,502 | -36.3% |
| Proceeds From Sale Of Property Plant And Equipment (FY) | — | — | — |
Show — breakouts |
|||
| Proceeds From Sale Of Property Plant And Equipment | 70 | 28,056 | -99.8% |
| Purchases of Investments (FY) | — | — | — |
Show — breakouts |
|||
| Purchases of Investments | -1,363,530 | -607,984 | -124.3% |
| Payments To Acquire Marketable Securities (FY) | — | — | — |
Show — breakouts |
|||
| Payments To Acquire Marketable Securities | -53,628 | -59,377 | +9.7% |
Show Investment Type breakouts |
|||
| Equity Securities | -53,628 | -59,377 | +9.7% |
| Proceeds From Sale Of Available For Sale Securities Debt (FY) | — | — | — |
Show — breakouts |
|||
| Proceeds From Sale Of Available For Sale Securities Debt | 783,896 | 549,609 | +42.6% |
| Proceeds From Sale And Maturity Of Marketable Securities (FY) | — | — | — |
Show — breakouts |
|||
| Proceeds From Sale And Maturity Of Marketable Securities | 58,808 | 48,127 | +22.2% |
Show Investment Type breakouts |
|||
| Equity Securities | 58,808 | 48,127 | +22.2% |
| Proceeds From Sale And Maturity Of Clearpoint Equity Investment (FY) | — | — | — |
Show — breakouts |
|||
| Proceeds From Sale And Maturity Of Clearpoint Equity Investment | 12,412 | — | — |
Show Investment Type breakouts |
|||
| ClearPoint Equity Investment | 12,412 | — | — |
| Payments To Acquire Intangible Assets (FY) | — | — | — |
Show — breakouts |
|||
| Payments To Acquire Intangible Assets | -291,152 | -67,747 | -329.8% |
| Net Cash from Investing (FY) | — | — | — |
Show — breakouts |
|||
| Net Cash from Investing | -861,984 | 44,182 | -2051.0% |
| Financing Activities | |||
| Proceeds From Stock Options Exercised (FY) | — | — | — |
Show — breakouts |
|||
| Proceeds From Stock Options Exercised | 93,102 | 28,565 | +225.9% |
| Proceeds From Stock Plans (FY) | — | — | — |
Show — breakouts |
|||
| Proceeds From Stock Plans | 5,944 | 5,199 | +14.3% |
| Proceeds From Sale Of Future Royalties (FY) | — | — | — |
Show — breakouts |
|||
| Proceeds From Sale Of Future Royalties | 240,000 | 241,792 | -0.7% |
| Payment For Contingent Consideration Liability Financing Activities (FY) | — | — | — |
Show — breakouts |
|||
| Payment For Contingent Consideration Liability Financing Activities | -6,341 | -18,200 | +65.2% |
| Payment Of Finance Lease Principal (FY) | — | — | — |
Show — breakouts |
|||
| Payment Of Finance Lease Principal | -1,611 | -1,490 | -8.1% |
| Net Cash from Financing (FY) | — | — | — |
Show — breakouts |
|||
| Net Cash from Financing | 331,094 | 255,866 | +29.4% |
| Supplemental | |||
| Interest Paid (FY) | — | — | — |
Show — breakouts |
|||
| Interest Paid | 5,702 | 5,823 | -2.1% |
| Income Taxes Paid (FY) | — | — | — |
Show — breakouts |
|||
| Income Taxes Paid | 36,854 | 17,550 | +110.0% |
| Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent (FY) | — | — | — |
Show — breakouts |
|||
| Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent | 518 | -57 | +1008.8% |
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability (FY) | — | — | — |
Show — breakouts |
|||
| Right Of Use Asset Obtained In Exchange For Operating Lease Liability | 27,675 | 6,462 | +328.3% |
| Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 (FY) | — | — | — |
Show — breakouts |
|||
| Noncash Or Part Noncash Acquisition Intangible Assets Acquired1 | 1,367 | 420 | +225.5% |
| Noncash Or Part Noncash Fixed Assets Tenant Improvement Allowance (FY) | — | — | — |
Show — breakouts |
|||
| Noncash Or Part Noncash Fixed Assets Tenant Improvement Allowance | 766 | 18,848 | -95.9% |
| Milestone Payable (Q) | — | — | — |
Show — breakouts |
|||
| Milestone Payable | 416 | 11,025 | -96.2% |
| Unpaid Capital Expenditures (FY) | — | — | — |
Show — breakouts |
|||
| Unpaid Capital Expenditures | 126 | 70 | +80.0% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations (FY) | — | — | — |
Show — breakouts |
|||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | 22,712 | -7,328 | +409.9% |
| Net Change in Cash (FY) | — | — | — |
Show — breakouts |
|||
| Net Change in Cash | 203,018 | 185,032 | +9.7% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents (Q) | — | — | — |
Show — breakouts |
|||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 998,334 | 795,316 | +25.5% |
| Income Tax Paid Federal After Refund Received (FY) | — | — | — |
Show — breakouts |
|||
| Income Tax Paid Federal After Refund Received | 26,640 | — | — |
| Income Tax Paid State And Local After Refund Received (FY) | — | — | — |
Show Income Tax Authority breakouts |
|||
| IL | 4,376 | — | — |
| State And Local Tax Jurisdiction Other | 854 | — | — |
| Income Tax Paid Foreign After Refund Received (FY) | — | — | — |
Show Income Tax Authority breakouts |
|||
| BR | 3,143 | — | — |
| Foreign Tax Jurisdiction Other | 1,841 | — | — |
Values in thousands USD. Source: SEC EDGAR 10-K filing.